1
BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)
(Set up the under the Dept. of Pharmaceuticals, Govt. of India)
Regd. Off.: Core No. 6, First Floor, SCOPE complex, Lodhi Road, New Delhi-110003
Working Office: IDPL Corporate Office, IDPL Complex, Old Delhi-Gurgaon Road,
Dundahera, Gurgaon-122016 (Haryana)
Phone numbers: 0124-4556751/ 52 Fax: 0124-2340370
e-mail : [email protected]; [email protected]
Website: janaushadhi.gov.in
TENDER FOR EMPANELMENT OF ANALYTICAL TESTING
LABORATORIES FOR THE ANALYSIS OF DRUGS AND
MEDICINES FOR THE YEAR 2014-2015
Tender Reference Number: BPPI/Drug Testing/004. Dt. 23/12/2013
Date of availability of Tender documents on website: 23/12/2013
Last date and time for receipt of Tender : 06/01/2014 at 15.00 hrs
Date and time of Opening of Tender : 06/01/2014 at 15.30 hrs
Place of Opening of Tender : BPPI, IDPL Corporate Office, IDPL
Complex, Dundahera, Gurgaon (HR)
Address For Communication : BPPI, IDPL Corporate Office, IDPL
Complex, Dundahera, Gurgaon (HR)
Contact Person for clarification if any: 1. Mr. K. Chopra,
Officer on Special Duty
0124-4040759, M-9711003043
Email: [email protected]
2. Mr. Mahadev Agarwal,
Manager (Regulatory)
0124-4556756, M-9873294473
Email: [email protected]
2
CONTENTS
Sl. No. Description Page No.
1 Last date for receipt of Tender 04
2 Eligibility Criteria 04
3 Earnest Money Deposit 05
4 Technical Bid – Cover -‘A’ 05
5 Price Bid – Cover -‘B’ 08
6 General Conditions 09
7 Acceptance of Tender 10
8 Opening of Cover -‘A’ and Cover-‘B’ of tender 10
9 Agreement 11
10 Security Deposit 11
11 Complete Analysis and Reporting Condition 12
12 Payment Provisions 15
13 Penalties Provisions 15
14 Black Listing Procedure 16
15 Jurisdiction 17
16 Agreement Format 17
17 Annexure-I : Proforma for Performance Statement 27
3
18 Annexure –II : Details of Laboratory and Certificate of
Registration for Service Tax
28
19 Annexure-III (A) Personnel in Laboratory 29
20 Annexure-III (B) List of Sophisticated Instruments 29
21 Annexure-III (C) Facilities in Microbiological Section 30
22 Annexure-IV: Declaration Form 31
23 Annexure V : List of Drugs and Medicines 32
24 Annexure VI : Checklist 49
25 Annexure VII : Cover -‘B’ (Price Bid) in a separate
cover
52
4
BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (Set up under dept. of Pharmaceuticals, Govt. of India)
TENDER FOR EMPANELMENT OF ANALYTICAL TESTING
LABORATORIES FOR THE ANALYSIS OF DRUGS AND MEDICINES
FOR BPPI FOR THE YEAR 2014-15 FROM THE DATE OF
ACCEPTANCE OF TENDER
“CONFIDENTIALITY IS THE ESSENCE OF THIS TENDER”
1. Sealed tenders will be received till 06/01/2014 upto 15.00 hour by General
Manager (A&F) at Bureau of Pharma Public Sector Undertakings of
India (BPPI), IDPL Corporate Office, IDPL Complex, Dundahera,
Gurgaon-122016 (Haryana), (Herein referred as Tender inviting
authority unless the context otherwise requires) for Empanelment of
Analytical Testing Laboratories for the Analysis of Drugs and Medicines
for Period of Two Years from the date of acceptance of tender by BPPI. The
tender may be extended for further period on mutually agreed terms.
2. (a) Only National Accreditation Board for Testing and Calibration
Laboratories (NABL) accredited analytical laboratories having license under
the Drugs and Cosmetics Act, with minimum two years experience in the
analysis of Drugs and medicines with an minimum average annual turnover of
5
Rs. 30 Lakhs for past two years (Govt./CPSU’s Laboratories, Research and
Development Laboratories, Laboratories run by Co-operative body and
Educational Institutions are exempted from the turnover criteria) however
turnover for the year 2012-13 should not be less than Rs. 30 lakhs, are eligible
to participate in the tender. Agents are not eligible to participate in the tender.
(b) Analytical Laboratory which has manufacturing activity of Drugs and
Medicines shall not be eligible to participate in the tender.
3. The complete set of tender document can be downloaded from the BPPI
website www.janaushadhi.gov.in and www.pharmaceuticals.gov.in free of
cost.
Submission of Tender Document:
4. The tenderer must submit the following documents in the sealed cover
superscribed Cover -‘A’ (all the documents have to be sealed and copies have
to be self attested and notarized in all pages).
[a]. The Earnest Money Deposit (EMD) shall be Rs.10,000/-( Rupees Ten
Thousand only) paid in the form of Demand Draft drawn in favour of
BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF
INDIA payable at Delhi/Gurgaon, should be sent with tender form in Cover-
6
‘A’. The EMD is refundable however it will not earn any interest. EMD in
the form of cheque/ cash/ postal order/ e-payment will not be accepted.
The EMD amount of unsuccessful bidder will be refunded to them within 30
days of finalization of tender. In respect of successful bidder (empanelled
bidder), the EMD amount will be adjusted towards security deposit.
[b]. Self attested and notarized Photocopies of Analytical Licence duly
renewed up to date, issued by the Drug Controller of the state and NABL
accreditation certificate.
[c]. Documentary evidence of having analyzed Drugs and medicines for the
last two years with the statement in the Proforma given in Annexure-I
[d]. Self attested and notarized photocopy of Certificate of Registration for
Service Tax should be enclosed in Annexure-II
[e]. Self attested and notarized document of the following should be furnished
in the format given in Annexure-III
(i). List of qualified personnel employed in the Laboratories along
with their experience and details of their approvals
(ii). The list of sophisticated instruments available in the Laboratory
7
(iii). Facilities available in Microbiological Section in the laboratory
[f]. A declaration in the Proforma given in Annexure-IV duly signed and
notarized.
[g]. Details of Drugs and medicines to be analyzed to be given in Annexure-V
[h]. Documentary evidence for the constitution of Labs viz. Memorandum
and Articles of Association, partnership deed etc, with details of name,
address, telephone no., fax no. e-mail address of Managing Director/ Partner/
Proprietor.
[i]. The instruments such as power of attorney, resolution of Board etc
authorizing the tenderer, should be enclosed in the tender (in Cover-‘A’) duly
signed by authorized signatory of the laboratory. Such Authorized Officer of
the tenderer should sign at the bottom of all the pages of the tender
documents.
5. Other Documents to be enclosed: [Self attested and notarized]
(i). Annual turnover statement certified by the auditors for last two years i.e.,
2011-12 and 2012-13.
(ii).The tenderer shall submit the checklist of documents in the enclosed
Proforma in Annexure –VI
8
Price Bid (Cover-‘B’)
6. (a). Price Bid (Annexure VII) of the tenderer duly filled in giving the rate
of testing, charges for complete testing of each sample and signed on each
page by Authorized person with company seal, should be sent in separate
sealed cover indicating name of the tenderer and superscribing “Price Bid”
Cover –‘B’ hereafter called Cover-‘B’.
(b). Cover-‘B’ shall contain the rates quoted by the tenderer only. It shall not
contain any other document. No condition shall be indicated in the Price Bid.
All the terms and conditions shall be indicated only in the Technical bid.
7.(a). The tender documents and certificates must be submitted in a separate
sealed cover as Cover-‘A’ and Price Bid shall be kept in separate sealed
cover as Cover-‘B’. Both Cover-‘A’ and Cover-‘B’ shall be kept in single
sealed cover on which it shall be superscribed as “TENDER FOR
EMPANELMENT OF ANALYTICAL TESTING LABORATORIES
FOR THE ANALYSIS OF DRUGS AND MEDICINES FOR TWO
YEARS FOR 2014-2015
9
(b). The tender document should reach General Manager, BPPI, IDPL
Corporate Office, IDPL Complex, Dundahera, Gurgaon-122016
(Haryana), till 06/01/2014 upto 15.00 hour.
(c). If the last date of submission is declared Holiday, the tenders may be
submitted on next working day upto 10.30 am.
(d).Tenderes should also enclose Soft Copy of Price Bid in CD along
with Cover-‘B’
General Conditions:
8. Forms in all Annexures should be filled up properly. Every correction
should invariably be attested by tenderer, failing which the tender will be
summarily rejected.
9. The tenderer should quote the rates for complete analysis for each drug and
medicine not for individual test to be performed.
10. The rates should be exclusive of taxes.
11. The rates quoted and accepted will be binding on the tenderer for
stipulated period and on no account any revision will be entertained till the
completion of the contract period.
10
12. The tender submitted by the laboratory which has been blacklisted by the
State / Central Govt. organization, shall not be considered.
ACCEPTANCE OF TENDER
13. Out of two covers submitted by each tenderer, Cover- ‘A’ will be opened
first at 15.30 hours on 06/01/2014 in the presence of tenderers or their
authorized representatives who chooses to be present. After scrutiny of the
documents and information furnished in Cover-‘A’ and confirmation of
details stated therein, a list of eligible laboratories will be shortlisted.
14. Cover-‘B’ (Price Bid) of the tenderers found eligible on the basis of
scrutiny of Cover-‘A’ will be opened subsequently and the date and time for
opening of Cover-‘B’ will be intimated to the shortlisted tenderers. The
acceptable rates for analysis will be decided on the basis of L1 rates and will
be communicated.
15. The tenderers other than L1 tenderer will be given opportunity to match
L1 rate and after due confirmation, their name/s will be included in the panel.
If required, the empanelled laboratories will be inspected by team of officials
of BPPI as and when need arises.
11
16. The tender inviting authority, BPPI reserves the right to accept or reject
any tender for any one or more of the items tendered for, without assigning
any reason.
17. No tenderer will be allowed to withdraw their bid after opening of Price
Bid.
AGREEMENT
18. All tenderer who are empanelled will have to execute an agreement on
non-judicial stamp paper of Rs. 100/-(stamp duty to be paid by tenderer) in
favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS
OF INDIA within 15 days from the date of intimation received by them from
BPPI that their tenders have been accepted. The form of Agreement is
enclosed in tender document.
SECURITY DEPOSIT
19. The successful tenderers must pay a security deposit of Rs. 20,000/-
(Rupees Twenty Thousand only) including adjustment of EMD amount at the
time of execution of agreement referred in Para 18 above by way of DD in
favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS
OF INDIA payable at Delhi/Gurgaon.
12
COMPLETE ANALYSIS AND REPORTING CONDITION
20. (a). On empanelment and entrustment of the job, the analytical laboratory
should furnish the test reports within,
(1). 8 days of receipt of sample in case of Tablet, Capsules, Ointment,
Cream, Gel, Powder and Liquid oral preparations.
(2). 21 days of receipt of sample in case of IV fluids and DPI (Dry
Powder Inject able)
(3). Within 24 hours of receipt of sample, the confirmation of receipt
should be given to BPPI by fax / mail.
(4). For any delay more than stipulated time in Para 20 (a)(1) and (2) as
the case may be, 1% of testing charges per week and the part thereof
would be deducted as penalty. If consecutively for 4 times or more
than 8 times in a year or a delay of more than 10 days occurs over the
time period stipulated above , then the penalty for subsequent delays
would be 2% of testing charges per week and part thereof.
13
(b). All the test mentioning IP, BP, USP should be carried out for each and
every sample. The results obtained in test should be mentioned in figures.
(c). “COMPLIES” or “PASSES” in result column of the report is treated as
incomplete report, if the result has some value.
(d). Every test report should have some specific remark as ‘Standard Quality’
or ‘Not of Standard Quality’.
(e). Report should have Sr.NO., Description of tests, specifications and results
obtained.
(f). Reports should be attached along with spectra or other data sheets, if
applicable.
(g). Report should be sent to General Manager (A and F), BPPI office as hard
copy and simultaneously scanned copy should be sent by e-mail
21. All test report should be submitted to BPPI in duplicate. In case of failure
of sample, result should be communicated immediately to Manager
Regulatory BPPI through phone/ fax/ e-mail and physical report should be
sent with covering letter addressed to General Manager (A&F) at Bureau of
14
Pharma Public Sector Undertakings of India (BPPI), IDPL Corporate Office,
IDPL Complex, Dundahera, Gurgaon-122016 (Haryana).
22. If in any circumstances (like breakdown of instrument or non-availability
of reference standard etc.) the analytical laboratory is unable to undertake
sample, the same should be reported within 24 hours of receipt of such
sample by fax/ e-mail to Manager Regulatory and sample should be returned
to him immediately.
23. If any sample is received in damaged condition by the laboratory, the
sample should not be analyzed and should be sent back immediately to
Manager Regulatory, BPPI and due information should be given by fax/ e-
mail.
24. Manager Regulatory, BPPI or authorized representatives have the right to
inspect the laboratories of the tenderer who have submitted tenders before
taking any decisions regarding empanelment. He may also inspect any
laboratory which is empanelled at any time during continuance of tender and
initiate action to terminate / cancel its empanelment of not to entrust any
further testing job to the laboratory if any violation of tender conditions are
noticed during such inspections.
15
PAYMENT PROVISIONS
25. No advance payment towards any analysis will be made to tenderer.
26. No payment will be made for incomplete analysis or incomplete report.
Refer Para 20 (b) to 20 (g)
27. (a) Payments towards the analysis of Drugs and Medicines will be made
along with Tax at the prevailing rate as applicable at the time of payment
strictly as per rules
(b) The bills should be submitted along with the copy of test report.
Efforts will be made to make payments within 30 days from the date of
receipt of the bills by BPPI if same are found in order in all respect.
PENALTIES PROVISIONS
28. If the successful tenderer fails to execute the agreement and payment of
security deposit after opening of Price Bid within the specified time or
withdraws the tender after the intimation of acceptance of tender has been
received by them or owing to any other reasons, the tenderer is unable to
undertake the contract, the empanelment will be cancelled and security
deposit shall stand forfeited to BPPI. Such tenderer will also be liable for all
16
damages sustained by BPPI by reasons of breach of tender conditions. Such
damages shall be assessed by CEO, BPPI whose decision shall be final.
29. (a). Non performance of any tenderer or empanelment conditions will
disqualify a laboratory to participate in the next tender.
(b). To assess the correctness of the test results being given by the
empanelled laboratory, samples would also be taken and sent randomly
to Govt. laboratory/ CPSUs Laboratories which are not empanelled for
testing and if any variation is found, the result would be informed to
empanelled laboratory. If there is any variation in the analytical reports
furnished by empanelled laboratories, (either pass or fail) with Govt.
/CPSUs Laboratory, the empanelled laboratory will be blacklisted for
two years besides forfeiture of security deposit, after giving due
opportunity to the concerned laboratory.
30. If it is revealed that analytical laboratory is involved in any form of fraud
and collusion with the suppliers of BPPI, the analytical laboratory will be
black listed for five years. The tenderer shall also be liable for action under
criminal law and matter will be informed to drugs controller for penal action
against them.
17
31. The CEO, BPPI will be at liberty to terminate the empanelment without
assigning any reasons. The tenderer will not be entitled for any compensation
whatsoever in respect of such termination.
32. In all matters pertaining to tender, the decision of CEO, BPPI shall be
final and binding.
33. In event of any dispute arising out of tender, such dispute would be
subject to the jurisdiction of civil court within Delhi.
34. In case of dispute or difference arising between BPPI and empanelled
analytical laboratory relating to any matter arising out of or connected with
this tender agreement, such dispute or differences shall be settled in
accordance with the Arbitration and Conciliation Act 1996. The venue of
arbitration shall be Gurgaon.
18
Contract for Empanelment of Analytical Testing Laboratories
For the Analysis of Drugs and Medicines
AGREEMENT
Agreement made this ________ day of at BPPI Gurgaon between M/s
_______ having its registered office at ________ (hereafter referred to as ‘The
Laboratory’ which term should include its successors, representatives, hires,
executors, and administrators unless excluded by contract) on one part and
BPPI having its registered office at New Delhi on other part.
Whereas the Laboratory has agreed to undertake the analytical work to the
BPPI, the list of medicines mentioned in the Schedule attached hereto at the
rates noted therein and in the manner and under the terms and conditions
hereinafter mentioned.
And whereas the Laboratory has deposited with the BPPI a sum of Rs 20000/-
(Rupees Twenty thousand only) as Security Deposit for the due and faithful
performance of this Agreement, to be forfeited in the event of the Laboratory
failing duly and faithfully to perform it.
Now these presents witness that for carrying out the said Agreement in this
behalf into execution, The Laboratory and the BPPI do hereby mutually
19
convenient, declare, contract and agree each of them with the other of them in
the manner following, that is to say,
(1). The term “Agreement”, wherever used in this connection, shall mean and
include the terms and conditions in tender floated by the BPPI for
Empanelment of analytical testing, laboratories for the analysis of Drugs and
medicines for the year 2014-2015 the instructions to tenderer, the conditions
of tender, acceptance of tender particulars hereinafter defined and those
general and special conditions that may be added from time to time.
(2). (a). The Agreement is for undertaking analysis of drugs and medicines by
the Laboratory to the BPPI of the samples specified in the Schedule attached
hereto at the rates noted against each therein on the terms and conditions set
forth in the Agreement.
(b). This Agreement shall be deemed to have come into force with effect from
_______________ and it shall remain in force for a period upto date of
______________ and may however be extended for a further period, on
mutually agreed terms.
20
INSPECTION OF LABORATORY
(3). In respect of the analysis medicines in the Schedule, the Laboratory shall
allow inspection of the Laboratory at any time during the tender period by a
team of Experts/Officials whom the BPPI may depute for the purpose. The
Laboratory shall extend all facilities to the team to enable them to inspect
sample and Standard storage, Reagents, Instruments, all other records,
Analysis etc., in the Laboratory.
RECOVERY OF MONEY DUE TO BPPI FROM THE LABORATORY:
(4). All expenses, damages and other money payable to the BPPI by the
Laboratory under any provisions of this Agreement may be recovered from
the amount due or subsequently becoming due from the BPPI to the
Laboratory under this or any other Agreement. In case such amounts are
insufficient to fully cover such expenses, damages or other money payable, it
shall be lawful for the BPPI to recover the balance amount from the security
deposit of the Laboratory and all other money held by BPPI and in case such
Security Deposit is insufficient, then it shall also be lawful for the BPPI to
recover the residue of the said expenses, damages and moneys, if necessary,
by resorting to legal proceedings against the Laboratory.
21
AMOUNT OF SECURITY DEPOSIT TO BE MADE BY THE
LABORATORY:
(5). The Laboratory shall deposit with the BPPI equivalent to an amount of
testing charges for samples quoted by them, subject to minimum of
Rs.20,000/-. The amount of Security Deposit shall be remitted by the
Laboratory to the BPPI by way of Demand Draft favoring BUREAU OF
PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA payable at
Delhi/Gurgaon. This agreement comes into effect only after the laboratory has
remitted the required amount of Security Deposit, not withstanding anything
contained in Para 2 (b) of this agreement.
SUBMISSION OF BILLS FOR UNDERTAKING ANALYSIS:
(6).(a). No advance payment towards any analysis will be made to the
Laboratory.
(b). All bills/invoices should be raised in duplicate in the name of General
Manager (A and F), BPPI. All payments shall be made by way of cheque
drawn in favour of Laboratory account and Crossed Account Payee / NEFT
only. The Laboratory shall furnish the details of their bank account no., name
22
of bank and branch, IFSC code No. etc to the BPPI. (An original cancelled
cheque leaf issued by their bank should be furnished).
ASSIGNMENT OF CONTRACT PROHIBITED:
(7). The Laboratory shall not, at any time, assign, sub-let or make over the
present contract or the benefits thereof or any part thereof, to any person or
persons whomsoever.
TERMINATION OF CONTRACT ON BREACH OF CONDITION:
(8). (a). In case the Laboratory fails or neglects or refuses to faithfully perform
any of the Covenants on his part herein contained or violets the condition in
the tender document, it shall be lawful for BPPI to forfeit the amount
deposited by the laboratory as security deposit and cancel the contract apart
from black listing the laboratory for period of two years.
(b). In case of laboratory fails or refuses to observe, perform fulfill and keep
all or any other or more or any part of anyone of covenants, stipulations and
provisions herein contain, it shall be lawful for BPPI on any such failure
neglect or refusal to put an end to this agreement and there upon every article
cause and thing herein contained on the part of BPPI shall cease and be void
and in case of any damage, loss, expense, differences in the cost or other
23
moneys than or any time during the continuance of this agreement becoming
due or owing by the laboratory to BPPI, it will be opened for BPPI to recover
from laboratory all such damages, losses, expenses, differences in cost nor
other moneys as aforesaid it shall be lawful for BPPI to appropriate the
security deposit made by laboratory as herein before mentioned to reimburse
all such damages, losses, expenses differences in cost and other moneys as
BPPI have sustained, incurred or put to by reason of the laboratory having
seen quality of any such failure, negligence or refusal as aforesaid or other
breach in the performance of contract.
(c). If at any time during the course of contract it is found that information by
the laboratory to BPPI, either in tender or otherwise, is false, BPPI may put an
end to contract / agreement wholly or in part and thereupon the provisions of
cause (a) shall apply.
(9). The BPPI reserves the right to terminate without assigning any reasons
therefore the contract/ agreement either wholly or in part without any notice
to the laboratory. The laboratory will not be entitled for any compensation
whatsoever in respect of such termination of contract by BPPI.
24
NOTICES ETC., IN WRITING
(10). All certificates or notices or orders for the time or for extra , varied or
altered laboratory, which are to be the subject of extra or varied charges
whether so described in the agreement or not, shall be in writing and unless in
writing shall not be valid, binding or be or any effect whatsoever.
LABORATORIES NOT TO HAVE ANY INTEREST IN THE
OFFICERS CONCERNED AND SUBORDINATED
(11). The laboratory shall not be in any way interested in or concerned directly
or indirectly with any of the officers, subordinates or servants of BPPI in
trade, business or transactions nor shall the laboratory give or pay or promise
to give or pay any such officer, subordinate or servant directly or indirectly
any money or fee or other consideration under designation of custom or
otherwise nor shall the laboratory permit any person or persons whomsoever
to interfere in the management or performance thereof under power of
attorney or otherwise without obtaining the consent of BPPI in writing.
BANKRUPTCY OF THE LABORATORY
(12). In case the laboratory at any time during the continuance of contact
becomes bankrupt or insolvent or commits any act of bankruptcy or
25
insolvency under the provisions of any law in that behalf for the time being in
force or should compound with his creditors, it shall be lawful for the BPPI to
put an end to the agreement, and there upon every article, para and thing
herein contend to be operative on the part of the BBPI, shall cease and be
void and the BPPI shall have the right and remedies given to him under the
president clauses.
SERVING OF NOTICES TO LABORATORY
(13). All notices or communications relating to or arising out this agreement or
any of the terms thereof shall be considered duly served on or given to the
laboratory if delivered to him or left at his premises, place of business or
above.
(14). And it is hereby agreed and declared between the parties hereto that in
case any question of dispute arises touching the construction or wording of
any Para herein contained on the rights, duties, liabilities of the parties hereto
or any other way, touching or arising out of the presents, the decision of CEO,
BPPI in the matter shall be final and binding.
(15). In the event of any disputes between the parties the dispute would be
subject to the jurisdiction of civil courts within Delhi only.
26
In witness where the laboratory and CEO acting for and on behalf of BPPI
have set their hands the day, month and year above written.
Authorized Signature of BPPI Authorized Signature of Laboratory
Name Name
Address and Seal Address and Seal
Witnesses for BPPI Witnesses for Laboratory
Signature Signature
Name Name
Address Address
27
ANNEXURE-I
Proforma for Performance Statement
(1). Name of Laboratory:
(2). Address:
(3). Performance Statement
Sr.
No.
Category No. of samples analyzed
during
Total no. of
Samples
2011-12 2012-13
1 Tablets
2 Capsules
3 LVP / SVP
4 Dry Powder
Injectables (DPI)
4 Liquid
Orals/Syrups
6 Ointments/
Creams/ Gel
7 Others
28
ANNEXURE-II
Details of Laboratory and Certificate of Registration for Service Tax
(1). Name of Laboratory
(2). Address of Head Office, if any:
(3). Address of Laboratory
(4). Name of contact person
(5). Phone No. :
Mobile No.:
(6). E-mail :
(7). Details of Licence issued by Drugs Regulatory Authority*
(8). Validity of Licence issued by Drugs Regulatory Authority:
(9). NABL Certificate No. along with discipline*
(10). Validity of NABL Certificate:
(11). Certificate of Registration for Service Tax: To be enclosed
(12). Any other certificates with details*
* enclose duly attested copy
29
ANNEXURE-III-A
Personnel in Laboratory
1) Total personnel engaged in Chemical / Instrumental analysis:
2) Total personnel engaged in Microbiological analysis:
3) Details of Competent (Approved) staff by State Licensing Authority
S.
No.
Name Designation Approval in Chemical /
Instrumental/
Microbiological Testing
Experience in
relevant
analysis (Years)
ANNEXURE-III-B
List of Sophisticated Instruments/ Apparatus in Laboratory
S. No. Name of
Instrument/
Apparatus
Make Date of Installation
Enclose additional paper
30
ANNEXURE-III-C
Facilities in Microbiological Section in Laboratory
1) List of cultures available: To be given
2) Details of equipments (e.g. Incubators, Laminar Air Flow etc.)
S. No. Name of
Instrument/
Apparatus
Make Date of Installation
Enclose additional paper
31
ANNEXURE-IV
Declaration Form (To be attested by Notary)
I / We _(Name of Bidder)_____________________________ having our
Head Office at ____________________ and Laboratory at
____________________ do declare that I / we carefully read all the
conditions of the tender of Bureau of Pharma Public Sector Undertakings of
India (BPPI), Gurgaon for empanelment of Analytical Testing Laboratories
for analysis of Drugs and Medicines for period 2014-2015 and abide by all
conditions said for therein.
I/We further declare that we have valid licence issued by Drug Regulatory
Authority bearing no. ____________ and NABL Certificate bearing no.
_________ in discipline ________.
Signature
Name of Authorized Person
Seal of Laboratory
32
Annexure – V
List of 361 Drugs and Medicines
BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016
Tender for Empanelment of Analytical Testing Laboratories for the Analysis of Drugs and Medicines for the Year 2014-2015
Sl. No
Drug Code
Generic Name of the Medicines Unit Size Quoted by laboratory
As symbol (√)
Or yes
ANALGESIC/ ANTI-INFLAMMATORY/ MUSCLOSKELETAL DISORDER
1 1 Aceclofenac 100 mg + Paracetamol 500mg Tablets 10x10
2 2 Aceclofenac Tablets I.P. strength 100 mg 10x10
3 3 Aceclofenac Gel 3%w/w 30 g tubes
4 4 Acetaminophen 325 mg + Tramadol Hydrochloride
37.5 mg Tablets film coated
10x10
5 5 Asprin Tablets I.P. strength 150 mg 14x10 6 6 Chlorzoxazone 500 mg + Diclofenac 50 mg +
Paracetamol 500 mg Tablets film coated
10x10
7 7 Diclofenac Gel
Diclofenac Diethylamine 1.16%w/w equiv. to diclofenac sodium 1%w/w
15 g
8 8 Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablets
10x10
9 9 Diclofenac Sodium (SR) 100 mg Tablets 10x10
10 10 Diclofenac Sodium Injection I.P. strength 25mg/ml 3 ml
11 11 Diclofenac Sodium Tablets I.P. strength 50mg 10x10 12 12 Etoricoxilb Tablets strength 120mg 10x10 13 13 Etoricoxilb Tablets 90mg 10x10
14 14 Ibuprofen 400 mg+ Paracetamol 325 mg Tablets 10x10 15 15 Ibuprofen Tablets I.P. film coated strength 200mg 10x10 16 16 Ibuprofen Tablets I.P. film coated strength 400 mg 10x10 17 17 Indomethacin Capsulesules I.P. strength 25 mg 10x10
18 18 Methyl Salicylate Oint. (Eutheria) Methyl Salicylate I.P. 11.25%w/v
Menthol I.P. 4.7%w/v
Eucalyptol I.P. 7.2%v/w
20 g
19 19 Nimesulide 100 mg+ Paracetamol 500mg Tablets 10x10 20 20 Nimesulide Tablets BP strength 100 mg 10x10
21 21 Paracetamol 325mg + Diclofenac Sodium 50 mg
Tablets
10x10
33
22 22 Paracetamol Syrup I.P. strength 125 mg /5 ml 60 ml
bottles
23 23 Paracetamol Tablets I.P. strength 500mg 10x10
24 24 Pentazocine Injection I.P. strength 30 mg/ ml 1 ml
25 25 Serratiopeptidase Tablets I.P. strength 10 mg 10x10
26 26 Tramadol Injection 100 mg 2ml
27 27 Tramadol Injection 50 mg 1ml
28 28 Tramadol Tablets 50 mg 10x10
ANTIBIOTICS
29 29 Acyclovir Tablets I.P. film coated strength 400 mg 10x10
30 30 Amikacin Injection I.P. strength 100mg Vial
31 31 Amikacin Injection I.P. strength 250mg Vial
32 32 Amikacin Injection I.P. strength 500mg Vial
33 33 Amoxycillin 250 mg + Bromhexine 8 mg Capsules 10x10
34 34 Amoxycillin 500 mg + Bromhexine 8 mg Capsules 10x10
35 35 Amoxycillin I.P. 1000 mg + Clavulanic acid I.P.
200mg Injection
Vial with
WFI
36 36 Amoxycillin I.P. 200 mg + Clavulanic acid 28.5 mg
/5ml Dry Syrup I.P.
30 ml
bottles
37 37 Amoxycillin I.P. 250 mg + Clavulanic acid I.P. 50 mg Injection
Vial with WFI
38 38 Amoxycillin I.P. 500 mg + Clavulanic acid I.P. 100mg
Injection
Vial with
WFI
39 39 Amoxycillin I.P. 500 mg + Clavulanic acid I.P. 125
mg Tablets film coated
6x10
40 40 Amoxycillin 250 mg+ Cloxacillin 250 mg Capsules 10x10
41 41 Amoxycillin 250 mg + Dicloxacillin 250 mg Capsules 10x10
42 42 Amoxycillin Kid Tablets I.P. strength 125 mg 10x10
43 43 Amoxycillin Dry Syrup I.P. strength 125mg/ 5ml 60 ml bottles
44 44 Amoxycillin Capsulesules I.P. strength 250 mg 10x10
34
45 45 Amoxycillin Capsulesules I.P. strength 500 mg 10x10
46 46 Ampicillin Injection I.P. strength 500mg Vial
47 47 Azithromycin Syrup I.P. strength 100mg/ 5ml 15 ml
bottles
48 48 Azithromycin Tablets DT strength 100 mg 10x10
49 49 Azithromycin Tablets I.P. film coated strength 250 mg
10x10
50 50 Azithromycin Tablets I.P. film coated strength 500
mg
10x10
51 51 Cefadroxil Tablets I.P. film coated strength 250 mg 10x10
52 52 Cefadroxil Tablets I.P. film coated strength 500 mg 10x10
53 53 Cefixime Dry Syrup I.P. strength 50 mg/ 5ml 30 ml
bottles
54 54 Cefixime Tablets I.P. film coated strength 100mg 10x10
55 55 Cefixime Tablets I.P. film coated strength 200mg 10x10
56 56 Cefoperazone 1g + Sulbactam 1g Injection Vial & WFI
57 57 Cefoperazone 500 mg + Sulbactam 500 mg Injection Vial & WFI
58 58 Cefoperazone Injection I.P. strength 1 gm Vial
59 59 Cefotaxime Sodium 1g + Sulbactam Sodium 500 mg
Injection
Vial & WFI
60 60 Cefotaxime Sodium 250 mg + Sulbactam Sodium 125
mg Injection
Vial & WFI
61 61 Cefotaxime Sodium 500 mg + Sulbactam Sodium 250 mg Injection
Vial & WFI
62 62 Cefotaxime Sodium Injection I.P. strength 1000mg Vial & WFI
63 63 Cefotaxime Sodium Injection I.P. strength 250 mg Vial & WFI
64 64 Cefotaxime Sodium Injection I.P. strength 500 mg Vial & WFI
65 65 Cefpodoxime Tablets DT strength 100 mg 10x10
66 66 Cefpodoxime Tablets I.P. film coated strength 200
mg
10x10
67 67 Ceftazadime Injection I.P. strength 1000 mg Vial & WFI
68 68 Ceftazadime Injection I.P. strength 250 mg Vial & WFI
35
69 69 Ceftazadime Injection I.P. strength 500 mg Vial & WFI
70 70 Ceftriaxone 1000 mg + Sulbactam 500 mg Injection Vial & WFI
71 71 Ceftriaxone 1000 mg + Tazobactum 125 mg
Injection Vial & WFI
72 72 Ceftriaxone 250 mg + Tazobactum 31.25 mg
Injection Vial & WFI
73 73 Ceftriaxone 250 mg +Sulbactam 125 mg Vial & WFI
74 74 Ceftriaxone 500 mg + Sulbactam 250 mg Vial & WFI
75 75 Ceftriaxone Injection I.P. strength 1 g Vial & WFI
76 76 Ceftriaxone Injection I.P. strength 250 mg Vial & WFI
77 77 Ceftriaxone Injection I.P. strength 500 mg Vial & WFI
78 78 Cefuroxime Axetil Tablets I.P. film coated strength
250 mg
10x10
79 79 Cefuroxime Axetil Tablets I.P. film coated strength 500mg
10x10
80 80 Cephalexin Tablets DT strength 125 mg 10x10
81 81 Cephalexin Capsulesules I.P. strength 250 mg 10x10
82 82 Cephalexin Capsulesules I.P. strength 500 mg 10x10
83 83 Ciprofloxacin 250 mg + Tinidazole 300 mg Tablets
film coated
10x10
84 84 Ciprofloxacin 500 mg + Tinidazole 600 mg Tablets
film coated
10x10
85 85 Ciprofloxacin Tablets I.P. film coated strength 250 mg
10x10
86 86 Ciprofloxacin Tablets I.P. film coated strength 500
mg
10x10
87 87 Clotrimazole Ointment I.P. strength 1% w/w 15 g tubes
88 88 Co-trimoxazole Suspension I.P. strength Sulphamethoxazole 200mg + Trimethoprim
40mg / 5ml
50 ml bottle
89 89 Co-trimoxazole Tablets I.P. (Double Strength)
strength Sulphamethoxazole 800 mg +
Trimethoprim 160mg
10x10
90 90 Co-trimoxazole Pead. Tablets I.P.
strength Sulphamethoxazole 100 mg + Trimethoprim 20mg
10x10
36
91 91 Co-trimoxazole Tablets I.P.
(Single Strength) strength Sulphamethoxazole 400 mg +
Trimethoprim 80mg
10x10
92 92 Doxycycline Capsulesules I.P. strength 100 mg 10x10
93 93 Erythromycin Stearate Tablets I.P. film coated strength 250 mg
10x10
94 94 Gentamycin Sulphate Injection I.P. strength 80 mg/ 2ml
2 ml
95 95 Levofloxacin Tablets I.P. film coated strength 250 mg 10x10
96 96 Levofloxacin Tablets I.P. film coated strength 500 mg
10x10
97 97 Meropenem Injection I.P. strength 1gm Vial & WFI
98 98 Norfloxacin 400 mg + Tinidazole 600 mg Tablets film
coated
10x10
99 99 Norfloxacin Tablets I.P. film coated strength 400 mg 10x10
100 100 Ofloxacin 200 mg + Ornidazole 500 mg Tablets film coated
10x10
101 101 Ofloxacin Tablets I.P. film coated strength 200 mg 10x10
102 102 Ofloxacin Tablets I.P. film coated strength 400 mg 10x10
103 103 Piperacillin 4 g + Tazobactum 0.5 mg Injection Vial & WFI
104 104 Roxithromycin Suspension strength 50 mg/ 5ml 30 ml
bottles
105 105 Roxithromycin Tablets I.P. film coated strength 150 mg
10x10
106 106 Roxithromycin Tablets I.P. film coated strength 300 mg
10x10
107 107 Tinidazole Tablets I.P. film coated strength 300 mg 10x10
108 108 Tinidazole Tablets I.P. film coated strength 500 mg 10x10
109 109 Vancomycin I.P. strength 500 mg Vial & WFI
ANTI INFECTIVES (TOPICALS)/ ANTIFUNGAL/
SKIN OINTMENT
110 110 Adapalene 0.1 % w/v Ointment 15 g tubes
111 111 Application Benzyl Benzoate Lotion I.P. strength 25 % w/w
100 ml
112 112 Beclomethasone 0.025%w/w + Clotrimazole 1.0% +
Gentamycin 0.1% w/w Cream
15 g tubes
37
113 113 Beclomethasone 0.025% w/w + Neomycin 0.5%
w/w Cream
15 g tubes
114 114 Beclomethasone Dipropionate Oint. I.P. strength 0.025% w/v
15 g tubes
115 115 Calamine Lotion I.P. 100 ml
bottles
116 116 Chlorhexidine Gluconate Solution I.P. strength 5% 500 ml
bottles
117 117 Chlorhexidine Gluconate 0.2% Mouth Wash 150 ml bottles
118 118 Clobetasol Propionate Cream strength 0.05 % w/w 15 g tubes
119 119 Fluconazole Tablets I.P. film coated strength 150 mg 10x10
120 120 Fusidic Acid Cream strength 2 % w/v 10 g tubes
121 121 Glutaraldehyde Solution strength 2% w/v 500 ml
bottles
122 122 Ketoconazole Lotion strength 2 % w/w 100 ml
bottles
123 123 Lignocaine Ointment strength 2% w/w 30 g tubes
124 124 Povidone Iodine Ointment strength 5% w/w 250 gm
tubes
125 125 Povidone Iodine Ointment strength 5% w/w 15 gm
tubes
126 126 Povidone Iodine Solution I.P. strength 10 % 500 ml bottles
127 127 Povidone Iodine Solution I.P. strength 5 % 100 ml
bottles
128 128 Povidone Iodine Solution I.P. strength 5 % 500 ml
bottles
129 129 Povidone Iodine Solution I.P. strength 7.5% 500 ml bottles
130 130 Solution Antiseptic
Chlorhexidine 1.5%w/v + Cetramide 3%w/v
Solution
100 ml
bottles
131 131 Silver Sulphadiazine Cream strength 1 % w/w 20 gm tubes
132 132 Silver Sulphadiazine Cream strength 1 % w/w 500 gm
jars
ANTIDIABETIC DRUGS
133 133 Glibenclamide Tablets (Scored Oval) I.P. strength
2.5 mg
10x10
134 134 Glibenclamide Tablets (Scored Oval) I.P. strength 5
mg
10x10
135 135 Gliclazide Tablets I.P. strength 40 mg 10x10
38
136 136 Gliclazide Tablets I.P. strength 80 mg 10x10
137 137 Glimeperide Tablets I.P. strength 1mg 10x10
138 138 Glimeperide Tablets I.P. strength 2mg 10x10
139 139 Glimeperide 1mg + Metformin 500mg + Pioglitazone
15mg
10x10
140 140 Glimeperide 2mg + Metformin 500mg + Pioglitazone 15mg
10x10
141 141 Glipizide 5 mg Tablets I.P. strength 10x10
142 142 Insulin Injection (Human) I.P. strength 40iu/ml 10 ml Vial
143 143 Insulin Injection {Insulin Human (Soluble 30% & Isophane 70%) 40iu/ml}
10 ml Vial
144 144 Metformin Hydrochloride SR Tablets I.P. strength
1000 mg
10x10
145 145 Metformin Hydrochloride Tablets I.P. strength
500mg
10x10
146 146 Pioglitazone Tablets I.P. strength 15 mg 10x10
147 147 Pioglitazone Tablets I.P. strength 30 mg 10x10
148 148 Pioglitazone 15 mg Tablets + Glimeperide 1mg 10x10
149 149 Pioglitazone 15 mg Tablets + Glimeperide 2mg 10x10
150 150 Pioglitazone 15 mg Tablets + Metformin 500mg 10x10
ANTI-MIGRAINE DRUGS
151 151 Dihydroergotamine Tablets film coated strength 1 mg
10x10
ANTI-NEOPLASTIC DRUGS
152 152 Bleomycin Injection I.P. strength 15 mg Vial
153 153 Cisplatin Injection 10 mg Vial
154 154 Cisplatin Injection I.P. strength 50 mg Vial
155 155 Doxorubicin Injection I.P. strength 10 mg Vial
156 156 Doxorubicin Injection I.P. strength 50 mg Vial
157 157 Etoposide Capsulesules I.P. strength 100 mg 10x10
39
158 158 Etoposide Injection I.P. strength 100 mg/5ml Vial
159 159 Gemcitabine Injection strength 1000 mg Vial
160 160 Gemcitabine Injection strength 200 mg Vial
161 161 Medroxyprogestrone Acetate Tablets film coated 10
mg
10x10
162 162 Raloxifene Tablets strength 60 mg 10x10
163 163 Tamoxifen Citrate Tablets I.P. strength 10 mg 10x10
164 164 Tamoxifen Citrate Tablets I.P. strength 20 mg 10x10
I. V. FLUIDS
165 165 Ciprofloxacin Infusion I.P. strength 2mg/ml 100 ml
bottles
166 166 Dextrose (10D) I.P. strength 10% 500 ml
bottles
167 167 Dextrose (5 D) I.P. strength 5% 500 ml
168 168 Glucose Normal Saline (DNS) Dextrose 5%w/v,
sodium chloride 0.9%w/v
500 ml
bottles
169 169 Levofloxacin Infusion I.P. strength 500 mg 100 ml
bottles
170 170 Mannitol I.P. strength 20% 100 ml bottles
171 171 Mannitol I.P. strength 20% 350 ml
172 172 Metronidazole Infusion I.P. strength 5 mg /ml 100 ml
173 173 Normal Saline (NS) I.P. strength 0.9%w/v 500 ml
174 174 Plasma Volume Expander (Gelatin Base) 500 ml
175 175 Ringer Lactate (RL) I.P. strength 10% infusion 500 ml
176 176 Water for Injection I.P. 5ml Amp
GASTROINTESTINAL TRACT/ ANTHELMINTICS
177 177 Albendazole Syrup Strength 200 mg/ 5ml 10 ml
bottles
178 178 Albendazole 400 mg + Ivermectin 6mg Tablets 10x1 Tablets
179 179 Albendazole Tablets I.P. strength 400mg 10x10
40
180 180 Bisacodyl Tablets I.P. strength 5mg 10x10
181 181 Cyproheptadine HCl 2 mg + Tricholine Citrate 275 mg Syrup
200 ml bottles
182 182 Dicyclomine 20 mg + Mefenamic Acid 250 mg
Tablets
10x10
183 183 Dicyclomine Tablets I.P. strength 10 mg 10x10
184 184 Dicyclomine HCl. & Paracetamol Tablets strength Dicyclomine HCl 20 mg
Paracetamol 325 mg
10x10
185 185 Diethylcarbamazine citrate Tablets I.P. film coated strength 100 mg
10x10
186 186 Domperidone Tablets I.P. strength 10 mg 10x10
187 187 Domperidone 5 mg. / 5 ml Syrup 30 ml
bottles
188 188 Dried Aluminum hydroxide 250mg + Magnesium Hydroxide 250mg + Simethicone 50mg Tablets
10x10
189 189 Enzyme Syrup Diastase(1:1200) 50mg
Pepsin (1:3000) 10mg per 5ml
200 ml bottles
190 190 Enzyme Tablets film coated 10x10
191 191 Famotidine Tablets I.P. strength 20 mg 10x10
192 192 Famotidine Tablets I.P. strength 40 mg 10x10
193 193 Furazolidone Tablets I.P. strength 100 mg 10x10
194 194 Hyoscine Butyl Bromide Tablets I.P. film coated
strength 10 mg
10x10
195 195 Ispagula Husk Powder I.P. 200 g
Pack
196 196 Lactobacillus 60 million spores Tablets 10x10
197 197 Lactulose Syrup strenth 10 g/15 ml 100 ml
bottles
198 198 Aluminium Hydroxide 250mg + Magnesium
Hydroxide 250mg / 5ml Suspension
170 ml
199 199 Metoclopramide Tablets I.P. strength 10 mg 10x10
200 200 Metoclopramide Injection I.P. strength 5mg/ml 2 ml
201 201 Metronidazole Tablets I.P. film coated strength 200
mg
10x10
202 202 Metronidazole Tablets I.P. film coated strength 400 mg
10x10
41
203 203 Misoprostol Tablets film coated 200 mcg 4x10
204 204 Norfloxacin 100 mg + Metronidazole 100 mg/5 ml Syrup
30 ml bottles
205 205 Ofloxacin 50 mg + Metronidazole 100mg/5 ml Syrup 30 ml
bottles
206 206 Omeprazole 20 mg + Domperidone 10 mg Capsules 10x10
207 207 Omeprazole Tablets film coated strenght 20 mg 10x10
208 208 Ondansetron Injection I.P. strength 2 mg/ml 2 ml
209 209 Ondansetron Tablets I.P. strength 4 mg 10x10
210 210 Ornidazole Tablets I.P. film coated strength 500 mg 10x10
211 211 Pantoprazole Tablets I.P. film coated strength 20 mg 10x10
212 212 Pantoprazole Tablets I.P. film coated strength 40 mg 10x10
213 213 Pantoprazolel Injection I.P. strength 40 mg/ 10m Vial
214 214 Rabeprazole 20 mg + Domperidone 30 mg Tablets
SR
10x10
215 215 Rabeprazole Tablets I.P. film coated strength 20 mg 10x10
216 216 Ranitidine Injection I.P. strength 50 mg/ 2ml 2ml
217 217 Ranitidine HCl Tablets I.P. film coated strength 150
mg
10x10
218 218 Ranitidine HCl Tablets I.P. film coated strength 300
mg
10x10
VITAMINS
219 219 Calcium carbonate 1250mg + Vitamin D3 250iu
Tablets film coated
10x10
220 220 Calcium carbonate 1250mg + Vitamin D3 500iu
Tablets film coated
10x10
221 221 Calcium Citrate 100 mg + Vitamin D3 125 iu Syrup 150 ml
bottles
222 222 Calcium with Minerals Suspension 150ml
223 223 Doxyalamine Succinate 10 mg + Pyridoxine 10 mg +
Folic Acid 2.5 mg Tablets film coated
10x10
224 224 Folic Acid Tablets I.P. strength 5mg 10x10
225 225 Iron + Folic Acid Syrup Ferrous Fumerate equivalent to elemental Iron 20mg, Folic
Acid 100 mcg per ml
200 ml bottles
42
226 226 Iron, Folic Acid & Zinc (Carbonil Iron) Capsules 15 x10
227 227 Polyvitamin (Prophylactic) NFI Tablets film coated 10x10
228 228 Tonic Iron, Folic Acid & Zinc (Carbonil Iron) Syrup 200 ml
bottles
229 229 Vitamin + Iron Tonic Syrup 100 ml
bottles
230 230 Vitamin B Complex with Vitamin C & Zinc (Cebexin -Z) Capsules
10x10
231 231 Vitamin B-Complex (Prophylactic) film coated
Tablets
10x10
232 232 Vitamin B-Complex NFI Syrup 200 ml
bottles
233 233 Vitamin-C Chewable Tablets I.P. strength 500mg 10x10
RESPIRATORY SYSTEM & ANTI-ALLERGICS
234 234 Budesonide Respule strength 0.25 mg/ml 2 ml
235 235 Budesonide Respule strength 0.5 mg/ml 2 ml
236 236 Budesonide 100 mcg/dose 30
Rotacaps
237 237 Budesonide 200 mcg 30
Rotacaps
238 238 Budesonide Inhaler strength 200 mcg/dose 200 md
239 239 Cetrizine Syrup I.P. strength 5mg/ 5ml 60 ml
bottles
240 240 Cetrizine Tablets I.P. film coated strength 10mg 10x10
241 241 Cough Syrup (Dextromethorphan Based) Syrup 100 ml bottles
242 242 Cough Syrup
Chlorpheniramine Maleate I.P. 3 mg + Ammonium
Chloride I.P. 110 mg + Sodium Citrate I.P. 46mg + Menthol I.P. 0.9mg
+Chloroform I.P. 0.5%w/v
110ml
bottles
243 243 Cough Syrup
Diphenhydramine 14mg + Ammonium Chloride I.P. 135mg + Sodium Citrate I.P. 57mg + Menthol I.P.
0.9mg
110ml
bottles
244 244 Etophyllin 84.7 mg + Theophylline 25.3 mg Injection 2 ml
245 245 Etophyllin 77 mg +Theophylline 23 mg Tablets 10x10
246 246 Fexofenadine Tablets I.P. film coated strength 120
mg
10x10
43
247 247 Fexofenadine Tablets I.P. film coated strength 180
mg
10x10
248 248 Levocetrizine Tablets I.P. film coated strength 5 mg 10x10
249 249 Levocetrizine HCl 5 mg + Pseudoephedrine 20 mg +
Paracetamol 325mg Tablets
10x10
250 250 Montelukast Sodium Tablets I.P. strength 5 mg 10x10
251 251 Montelukast Sodium Tablets I.P. strength 10 mg 10x10
252 252 Montelukast Sodium 10 mg + Levocetrizine 5mg
Tablets film coated
10x10
253 253 Pheniramine Maleate Tablets I.P. strength 25 mg 10x10
254 254 Promethazine Syrup I.P. strength 5 mg/ 5ml 100ml bottles
255 255 Salbutamol Inhaler I.P. strength 100 mcg/puff 200 md
256 256 Salbutamol Tablets I.P. strength 2 mg 10x10
257 257 Salbutamol Respule strength 2.5 mg 2.5 ml
258 258 Salbutamol 200 mcg 30
Rotacaps
259 259 Salbutamol Syrup I.P. strength 2mg /5ml 100 ml
bottles
260 260 Salbutamol Tablets I.P. strength 4 mg 10x10
CARDIOVASCULAR DRUGS/
DIURETICS/HYPOLIPIDAEMIC AGENT/ANTI-
COAGULANT
261 261 Adenosine 6 mg/ 2ml Amp. 2 ml
262 262 Amiodarone Tablets I.P. strength 100 mg 10x10
263 263 Amlodipine 5 mg + Atenolol 50 mg Tablets film coated
10x10
264 264 Amlodipine Tablets I.P. film coated strength 5mg 10x10
265 265 Atenolol Tablets I.P. strength 50 mg 14x10
266 266 Atorvastatin film coated Tablets I.P. strength 10mg 10x10
267 267 Atorvastatin Tablets film coated strength 20 mg 10x10
268 268 Clonidine Tablets I.P. strength 0.1 mg 10x10
269 269 Clopidogrel Tablets I.P. strength 75mg 10x10
44
270 270 Clopidogrel 75mg Tablets + Aspirin 75 mg 10x10
271 271 Diltiazem Tablets I.P. strength 30 mg 10x10
272 272 Diltiazem Tablets I.P. strength 60 mg 10x10
273 273 Dobutamine Injection strength 250 mg/ 20ml Vial
274 274 Dopamine HCl Injection strength 200 mg/5ml 5 ml
275 275 Enalpril Tablets I.P. strength 5mg 10x10
276 276 Enoxaparin Injection I.P. strength 40mg/0.4ml 0.4 ml
277 277 Enoxaparin Injection I.P. strength 60 mg/0.6 ml 0.6 ml
278 278 Frusemide Injection I.P. strength 10 mg/ml 2ml
279 279 Frusemide Tablets I.P. strength 40 mg 10x10
280 280 Heparin Sodium Injection I.P. strength 1000iu/ml
5 ml
281 281 Heparin Sodium Injection I.P. strength 5000iu/ ml 5 ml
282 282 Hydrochlorothiazide Tablets I.P. strength 12.5 mg 10x10
283 283 Isosorbide Dinitrate Tablets I.P. strength 10 mg 10x10
284 284 Isosorbide Mononitrate Tablets I.P. strength 10 mg 10x10
285 285 Lisinopril 5 mg + Amlodipine 5mg Tablets 10x10
286 286 Lisinopril Tablets I.P. strength 5mg 10x10
287 287 Losartan I.P. 50 mg & Hydrochlothaizide I.P. 12.5mg
Tablets film coated
10x10
288 288 Losartan film coated Tablets I.P. strength 25mg 10x10
289 289 Losartan PotassiumTablets I.P. film coated strength 50 mg
10x10
290 290 Metoprolol Tablets I.P. strength 25 mg 10x10
291 291 Metoprolol Tablets I.P. strength 50 mg 10x10
292 292 Nifedipine Capsulesules I.P. strength 10 mg 10x10
293 293 Ramipril Tablets I.P. strength 2.5 mg 10x10
45
294 294 Ramipril Tablets I.P. strength 5 mg 10x10
295 295 Simvastatin Tablets I.P. strength 10 mg 10x10
296 296 Simvastatin Tablets I.P. strength 20 mg 10x10
297 297 Tamsulosin Hydrochloride 0.4 mg Capsules 10x10
298 298 Telmisartan 40 mg + Hydrochlorthiazide 12.5 mg Tablets
10x10
299 299 Telmisartan Tablets I.P. strength 20 mg 10x10
300 300 Telmisartan Tablets I.P. strength 40 mg 10x10
301 301 Tranexamic Acid Tablets strength 500 mg 10x10
302 302 Tranexamic Acid Injection strength 500 mg/5ml 5 ml Amp.
ANTIMALARIAL DRUGS
303 303 Artesunate Tablets strength 50mg 10x10
304 304 Arteether Injection I.P. strength 150mg 2ml Vial
305 305 Chloroquine Phosphate Tablets I.P. film coated
strength 250 mg
10x10
306 306 Primaquine Tablets I.P. film coated strength 15 mg 10x10
307 307 Primaquine Tablets I.P. film coated strength 2.5 mg 10x10
308 308 Primaquine Tablets film coated 5 mg 10x10
309 309 Sulphadoxine 250 mg + Pyrimethamine 12.5 mg/5ml Syrup
10 ml bottles
310 310 Sulphadoxine I.P. 500 mg + Pyrimethamine I.P. 25
mg Tablets
(2X5X10)
ELECTROLYTES
311 311 Disodium hydrogen Citrate (Alkalyser) 1.4 mg/5ml Syrup
100 ml bottles
312 312 Oral Rehydration Salts Citrate IP (WHO Formula)
Sachet I.P. strength 21 GM
1S
CNS DRUGS/ANTI-EPILEPTIC DRUGS
313 313 Alprazolam film coated Tablets I.P. strength 0.25 mg 10x10
314 314 Alprazolam film coated Tablets I.P. strength 0.5 mg 10x10
46
315 315 Betahistine Tablets I.P. strength 16 mg 10x10
316 316 Betahistine Tablets I.P. strength 8 mg 10x10
317 317 Carbamazepine Tablets I.P. strength 100mg 10x10
318 318 Carbamazepine Tablets I.P. strength 200mg 10x10
319 319 Clonazepam Tablets I.P. strength 0.5 mg 10x10
320 320 Diazepam Tablets I.P. strength 5 mg 10x10
321 321 Escitalopram Tablets I.P. strength 10 mg 10x10
322 322 Escitalopram Tablets I.P. strength 20 mg 10x10
323 323 Flunarzine Tablets strength 10mg 10x10
324 324 Flunarzine Tablets strength 5mg 10x10
325 325 Fluoxetine hydrochloride Capsulesules I.P. strength 20 mg
10x10
326 326 Methyl Ergometrine Tablets I.P. strength 0.125mg 10x10
327 327 Phenytoin Sodium Tablets I.P. strength 100 mg 10x10
328 328 Prochlorperazine Tablets I.P. strength 5 mg 10x10
CORTICO – STEROIDS/DRUG USED IN
HYPOTHYRIODISM
329 329 Prednisolone Tablets I.P. strength 5 mg 10x10
330 330 Prednisolone Tablets I.P. strength 10 mg 10x10
331 331 Thyroxine Sodium Tablets I.P. strength 50 mcg 10x10
332 332 Thyroxine Sodium Tablets I.P. strength 100 mcg 10x10
333 333 Dexamethasone Tablets I.P. strength 0.5 mg 10x10
334 334 Dexamethasone Injection I.P. strength 40 mg 2 ml
DIETARY SUPPLEMENT
47
335 335 Protein Powder Protein
hydrolysate 16.8g vit A 1600iu, C 25mg, B1 1mg, B2-1.37mg, B6-0.5mg, B12-0.5mcg, E 5iu, D3-100iu,
B3-0.13mg, malt ext. 4.8g, d-penthol 1mg, cal. Phos. 0.4g, pot. 0.13mg, folic acid 50mcg, choline bitart
0.15g ferrous gluconate 17mg, per 30gm
200 g Jar
DRUGS USED IN GOUT
336 336 Allopurinol Tablets I.P. strength 100 mg 10x10
HORMONES AND RELATED DRUGS
337 337 Clomiphene citrate Tablets I.P. strength 50 mg 10x10
OPHTHALMIC PREPARATION
338 338 Atropine Sulphate Injection I.P. strength 0.6mg/ ml 1ml
339 339 Betaxolol Hydrochloride 0.5 % w/w Eye Drop 5 ml
340 340 Acyclovir 3% w/w Eye Onit. 5 g
341 341 Carboxymethyl Cellulose 0.5 % w/v Eye Drop 10 ml
342 342 Chloramphenicol Eye Drop I.P. strength 1 % w/v 5 ml
343 343 Chloramphenicol Eye Applicaps I.P. strength 1 % w/v 100
Applicaps
344 344 Ciprofloxacin Eye Drop I.P. strength 0.3% w/v 5 ml
345 345 Gentamycin Eye Drop I.P. strength 0.3% w/v 5 ml
346 346 Ketorolac Tromethamine Eye Drop 0.5 % w/v 5 ml
347 347 Prednisolone Acetate 1 % w/v Eye Drop 5 ml
348 348 Sulphacetamide Sodium Eye Drop I.P. strength 10 % w/v
10 ml
349 349 Sulphacetamide Sodium Eye Drop I.P. strength 20 %
w/v
10 ml
350 350 Timolol Maleate Eye Drop I.P. strength 0.5 % w/v 5 ml
OROPHARYNGEAL
351 351 Xylometazoline Nasal Drop I.P. strength 0.1 % w/v 10 ml
SURGICAL ANESTHETICS
48
352 352 Bupivacaine Hydrochloride Injection I.P. strength
0.5% w/w
4 ml X 5
353 353 Ketamine Hydrochloride Injection I.P. strength 10 mg/ml
10 ml
354 354 Ketamine Hydrochloride Injection I.P. strength 50
mg/ml
2 ml
355 355 Lignocaine Injection I.P. strength 1% w/v 20 ml Vial
356 356 Lignocaine Injection I.P. strength 2% w/v 20 ml Vial
357 357 Lignocaine I.P. 1% + Adrenaline I.P. 2% w/v
Injection
30 ml Vial
358 358 Propofol Injection I.P. strength 10 mg/ml 10ml Vial
VACCINES
359 359 Tetanus Toxoid Injection 0.5 ml
Amp.
OTHERS
360 360 Mifepristone 200 mg Tablets 1x10
361 361 Oxytocin Injection I.P. strength 5 iu / ml 1 ml Amp.
49
Annexure – VI
CHECK LIST COVER - A.
1. Checklist – Annexure VI Page No. Yes No
2. EMD in the form of DD shall be kept
in an envelope.
Page No. Yes No
3. Self attested and notorised Photo copy
of licence for Analytical laboratory
renewed upto date.
Page No. Yes No
4. Annexure – I
Proforma for performance statement
Page No. Yes No
5. Annexure – II
Details of Laboratory and Certificate
of Registration for service tax
Page No. Yes No
Annexure – III
Self attested and notorised of the following
documents:
6. Annexure – III (A)
Personnel in Laboratory.
Page No. Yes No
50
7. Annexure – III (B)
List of Sophisticated instruments.
Page No. Yes No
8. Annexure – III (C)
Facilities in Microbiological section
Page No. Yes No
9. Annexure – IV
Declaration form duly signed &
notorised.
Page No. Yes No
10. Annexure - V
List of Drugs and medicines
Page No. Yes No
11. Recognition Certificate issued
by NABL
Page No. Yes No
12. Certificate for analysis issued by other
recognized agencies
Page No. Yes No
13. Documentary evidence, for the
constitution of the company / laboratory
ie., Memorandum and articles of
Association or partnership etc.,
Page No. Yes No
14. The instruments such as power of
attorney, resolution of board etc.,
Page No. Yes No
51
15. Annual Turn over for the last two
years certified by the auditors.
Page No. Yes No
16. The tender document signed by the
tenderer in all pages with official seal
Page No. all Yes No
Cover B: (Price Bid) in a separate cover
17 Annexure VII Page No. Yes No
52
Annexure – VII
Price Bid
S.
No
.
Drug
Cod
e
Name of
Medicin
e
Rate
excludin
g Tax
Tax
applicab
le in %
Total
including
Taxes
Remark
s
Enclose Soft Copy of Price Bid (in Excel Sheet) in CD also.
Top Related